Immunoassays: Technologies and Global Markets

Immunoassays: Technologies and Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Immunoassays: Technologies and Global Markets

http://www.reportbuyer.com/pharma_healthcare/technology/immunoassays_technologies_global_markets.html

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC's goal in conducting this study was to determine the current status of the worldwide demand for immunoassays and to assess its growth potential over the five-year period from 2012 to 2017. We were particularly interested in the key industry applications of immunoassay technology in the U.S., Europe, Africa, the Middle East, and Asia. In addition, we were interested in the market potential for key prevailing immunoassay technology applications. Our main objective was to present a comprehensive analysis of the current immunoassay technology markets and its future direction.

REASONS FOR DOING THIS STUDY

Immunoassays represent one of the most used testing methodologies in the world today. Hence, we were interested in determining the different immunoassay applications and examining their growth potential. We also were especially interested in determining the types of technologies currently in use and their specific applications.

BCC has over the past several years examined the biological technology industry. Within this period, Immunoassay technology used in various types of medical and other diagnostics-type applications has taken diverse configurations. As a consequence, the use of this technology is changing with time. Therefore, BCC wanted to conduct a thorough and detailed analysis of immunoassay technology and project its growth potential.

CONTRIBUTIONS TO THE STUDY AND FOR WHOM

We have compiled a study of current immunoassay testing procedures markets and new emerging immunoassay technology markets. We present the economic environment of the immunoassay examination industry, technological descriptions and issues, applications, market factors, and potential, and project growth trends for the period of year 2012 to 2017. We also project market values and the distribution of immunoassay testing applications by the major market segments. This study will be of interest to the medical laboratory, in vitrodiagnostics, biotechnologies, medical diagnostic products, and drug testing industries. It will also be of interest to biological detection device hardware and software developers, manufacturing companies, and distributors.

SCOPE AND FORMAT

The scope of this study encompasses an investigation of the markets for the following immunoassay testing categories: enzyme, fluorescence, radio-immunoassay (RIA), cardiac analysis, infectious diseases, and tumor diagnosis. BCC analyzes each immunoassay examination type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues including the latest trends are discussed. BCC analyzes the industry on a worldwide basis, both from an application and demand point of view in the major regions of the world.

METHODOLOGY

BCC presents an analysis of each diagnostic application type and its estimated demand in 2012. Our estimated values are based on how much buying entities can be expected to pay in un-depreciated dollars. We then analyzed the potential applications for each usage in the field of immunoassay testing, and forecast the market size for 2012 and 2017. We also analyzed the demand for immunoassay analysis by major geographical market segments. All tables and figures are calculated in 2012 constant U.S. dollars.

INFORMATION SOURCES

BCC analyzed data produced by U.S. government agencies, industry trade associations, and international organizations to obtain data for this study. We also spoke with manufacturers of various immunoassay technology types in the U.S., the European Union, and Japan. In addition, we compiled data from current financial and trade information sources.

REPORT HIGHLIGHTS

This report provides:
• An overview of the global market for growth of immunoassay technology in clinical, food safety, and environmental areas.
• Analysis of global market trends, with data provided for 2011 and 2012, and projections, with five-year compound annual growth rates (CAGRs), through 2017.
• Discussion of government regulations and technology patents and the roles they play in development.
• Analysis of new markets.
• Comprehensive company profiles of major players.


TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
CONTRIBUTIONS TO THE STUDY AND FOR WHOM 2
SCOPE AND FORMAT 3
METHODOLOGY 3
INFORMATION SOURCES 3
RELATED REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL DEMAND FOR IMMUNOASSAYS BY REGION,
THROUGH 2017 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL DEMAND FOR IMMUNOASSAYS BY REGION,
2011-2017 ($ MILLIONS) 7


CHAPTER 3 OVERVIEW 9

IMMUNOASSAYS 9
ENZYME IMMUNOASSAYS 10
TABLE 1 ADVANTAGES OF ENZYME IMMUNOASSAY 10
TABLE 2 LIMITATIONS OF ENZYME IMMUNOASSAY 11
FLUORESCENT IMMUNOASSAYS 11
TABLE 3 ADVANTAGES OF FLUORESCENT IMMUNOASSAY 11
TABLE 4 LIMITATIONS OF FLUORESCENT IMMUNOASSAY 12
IMMUNOASSAY TECHNOLOGIES 12
DISPOSABLE MATRIX DEVICES 13
Handheld Immunochromatographic Assays (HHAs) 13
BTA Test Strips 13
Sensitive Membrane Antigen Rapid Test (SMART) 13
REAGENT TAG BIOSENSOR APPROACHES 14
NO-TAG REAGENT BIOSENSOR METHODS 14
RADIOISOTOPES 15
TABLE 5 ADVANTAGES OF RADIOISOTOPES 15
TABLE 6 LIMITATIONS OF RADIOISOTOPES 15

CHAPTER 4 GLOBAL TRENDS IMPACTING DEMAND FOR IMMUNOASSAY TESTING 18

MEDICAL AND RESEARCH LABORATORY SUPPLIES INDUSTRY TRENDS 18
DEMOGRAPHIC CHANGE 18
THE MAJOR U.S. COMPETITORS 19
GLOBAL DEMAND TRENDS 19
TABLE 7 GLOBAL MEDICAL PRODUCTS MARKET, 2012-2017 ($ BILLIONS) 19
INDUSTRY TRADE OBSTACLES AND OPPORTUNITIES 20
DRUG TESTING TRENDS 20

CHAPTER 5 THE GLOBAL MARKET 22

WORLD DEMAND FOR IMMUNOASSAYS 22
EUROPEAN DEMAND FOR IMMUNOASSAYS 22
TABLE 8 WESTERN EUROPEAN DEMAND FOR IMMUNOASSAYS BY COUNTRY
THROUGH 2017 ($ MILLIONS) 22
TABLE 9 EASTERN EUROPEAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 25
ASIAN DEMAND FOR IMMUNOASSAYS 26
TABLE 10 ASIAN DEMAND FOR IMMUNOASSAYS BY COUNTRY, THROUGH
2017 ($ MILLIONS) 26
TABLE 11 OCEANIA DEMAND FOR IMMUNOASSAYS BY COUNTRY, THROUGH
2017 ($ MILLIONS) 27
TABLE 12 SOUTHEAST ASIAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 28
THE AMERICAS' DEMAND FOR IMMUNOASSAYS 29
TABLE 13 NORTH AMERICAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 29
TABLE 14 CENTRAL AND SOUTH AMERICAN DEMAND FOR IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 30
AFRICAN DEMAND FOR IMMUNOASSAYS 31

TABLE 15 NORTH AFRICAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 31
SUB-SAHARAN AFRICAN DEMAND FOR IMMUNOASSAYS 32
TABLE 16 SUB-SAHARAN AFRICAN DEMAND FOR IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 32
MIDDLE EASTERN DEMAND FOR IMMUNOASSAYS 33
TABLE 17 MIDDLE EASTERN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 34

CHAPTER 6 ENZYME IMMUNOASSAYS 37

TABLE 18 GLOBAL DEMAND FOR ENZYME IMMUNOASSAY BY REGION,
THROUGH 2017 ($ MILLIONS) 37
EUROPEAN DEMAND FOR ENZYME IMMUNOASSAYS 37
TABLE 19 WESTERN EUROPEAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 38
TABLE 20 EASTERN EUROPEAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 41
ASIAN DEMAND FOR ENZYME IMMUNOASSAYS 42
TABLE 21 ASIAN DEMAND FOR ENZYME IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 42
TABLE 22 OCEANIA DEMAND FOR ENZYME IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 43
TABLE 23 SOUTHEAST ASIAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 44
THE AMERICAS' DEMAND FOR ENZYME IMMUNOASSAYS 45
TABLE 24 NORTH AMERICAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 45
TABLE 25 CENTRAL AND SOUTH AMERICAN DEMAND FOR ENZYME
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 46
AFRICAN DEMAND FOR ENZYME IMMUNOASSAYS 47
TABLE 26 NORTH AFRICAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 47
TABLE 27 SUB-SAHARAN AFRICAN DEMAND FOR ENZYME IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 48
MIDDLE EASTERN DEMAND FOR ENZYME IMMUNOASSAYS 49
TABLE 28 MIDDLE EASTERN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 50

CHAPTER 7 FLUORESCENT IMMUNOASSAYS 53

TABLE 29 GLOBAL DEMAND FOR FLUORESCENT IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 53
EUROPEAN DEMAND FOR FLUORESCENT IMMUNOASSAYS 53
TABLE 30 WESTERN EUROPEAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 54
TABLE 31 EASTERN EUROPEAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 56
ASIAN DEMAND FOR FLUORESCENT IMMUNOASSAYS 56
TABLE 32 ASIAN DEMAND FOR FLUORESCENT IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 57
TABLE 33 OCEANIA DEMAND FOR FLUORESCENT IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 58
TABLE 34 SOUTHEAST ASIAN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 58
THE AMERICAS' DEMAND FOR FLUORESCENT IMMUNOASSAYS 59
TABLE 35 NORTH AMERICAN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 59
TABLE 36 CENTRAL AND SOUTH AMERICAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 60
AFRICAN DEMAND FOR FLUORESCENT IMMUNOASSAYS 61
TABLE 37 NORTH AFRICAN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 61
TABLE 38 SUB-SARAHAN AFRICAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 62
MIDDLE EASTERN DEMAND FOR FLUORESCENT IMMUNOASSAYS 63
TABLE 39 MIDDLE EASTERN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 63

CHAPTER 8 RADIOIMMUNOASSAY 66

TABLE 40 GLOBAL DEMAND FOR RADIOIMMUNOASSAYS BY REGION,
THROUGH 2017 ($ MILLIONS) 66
EUROPEAN DEMAND FOR RADIOIMMUNOASSAYS 67
TABLE 41 WESTERN EUROPEAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 67
TABLE 42 EASTERN EUROPEAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 69
ASIAN DEMAND FOR RADIOIMMUNOASSAYS 69
TABLE 43 ASIAN DEMAND FOR RADIOIMMUNOASSAY BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 69
TABLE 44 OCEANIAN DEMAND FOR RADIOIMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 71
TABLE 45 SOUTHEAST ASIAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 71
THE AMERICAS' DEMAND FOR RADIOIMMUNOASSAYS 72
TABLE 46 NORTH AMERICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 72
TABLE 47 CENTRAL & SOUTH AMERICAN DEMAND FOR RADIO -
IMMUNOASSAYS BY COUNTRY,THROUGH 2017 ($ MILLIONS) 73
AFRICAN DEMAND FOR RADIOIMMUNOASSAYS 73
TABLE 48 NORTH AFRICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 74
TABLE 49 SUBSARAHAN AFRICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 75
MIDDLE EASTERN DEMAND FOR RADIOIMMUNOASSAYS 76
TABLE 50 MIDDLE EASTERN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 76

CHAPTER 9 DIABETES LABORATORY IMMUNOASSAY 79

TABLE 51 GLOBAL DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS
BY REGION, THROUGH 2017 ($ MILLIONS) 79
EUROPEAN DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS 80
TABLE 52 WESTERN EUROPEAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 80
TABLE 53 EASTERN EUROPEAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 82
ASIAN DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS 83
TABLE 54 ASIAN DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 83
TABLE 55 OCEANIA DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 84
TABLE 56 SOUTHEAST ASIAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 84
THE AMERICAS' DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS 85
TABLE 57 NORTH AMERICAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 85
TABLE 58 CENTRAL AND SOUTH AMERICAN DEMAND FOR DIABETES
LABORATORY IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 86
AFRICAN DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS 86
TABLE 59 NORTH AFRICAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 87
TABLE 60 SUBSARAHAN AFRICAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 87
MIDDLE EASTERN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS 88
TABLE 61 MIDDLE EASTERN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 89

CHAPTER 10 IMMUNOASSAYS FOR DRUG SCREENING 92

TABLE 62 GLOBAL DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 92
EUROPEAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS 92
TABLE 63 WESTERN EUROPEAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 93
TABLE 64 EASTERN EUROPEAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 95
ASIAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS 95
TABLE 65 ASIAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 96
TABLE 66 OCEANIAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 97
TABLE 67 SOUTHEAST ASIAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 97
THE AMERICAS' DEMAND FOR DRUG SCREENING IMMUNOASSAYS 98
TABLE 68 NORTH AMERICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 98
TABLE 69 CENTRAL AND SOUTH AMERICAN DEMAND FOR DRUG
SCREENING IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 99
AFRICAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS 100
TABLE 70 NORTH AFRICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 100
TABLE 71 SUBSAHARIAN AFRICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 100
MIDDLE EASTERN DEMAND FOR DRUG SCREENING IMMUNOASSAYS 101
TABLE 72 MIDDLE EASTERN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 102

CHAPTER 11 INFECTIOUS DISEASE IMMUNOASSAYS 105

TABLE 73 GLOBAL DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 105
EUROPEAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS 106
TABLE 74 WESTERN EUROPEAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 106
TABLE 75 EASTERN EUROPEAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 107
ASIAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS 108
TABLE 76 ASIAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 108
TABLE 77 OCEANIAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 109
TABLE 78 SOUTHEAST ASIAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 109
THE AMERICAS' DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS 110
TABLE 79 NORTH AMERICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 110
TABLE 80 CENTRAL AND SOUTH AMERICAN DEMAND FOR INFECTIOUS
DISEASE IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 111
AFRICA DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS 111
TABLE 81 NORTH AFRICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 112
TABLE 82 SUBSARAHAN AFRICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 113
MIDDLE EASTERN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS 114
TABLE 83 MIDDLE EASTERN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 114

CHAPTER 12 COMPANY PROFILES 117

TABLE 84 RANKING OF LEADING IMMUNOASSAY TECHNOLOGY
MANUFACTURERS 117
ABBOTT DIAGNOSTICS 117
ACON LABORATORIES INC. 118
AMAR IMMUNODIAGNOSTICS 118
BAYER AG 119
BECKMAN COULTER INC. 119
HISTORY OF BECKMAN COULTER MANUAL IMMUNOASSAYS 119
IMMUNOTECH 120
DIAGNOSTIC SYSTEMS LABORATORIES (DSL) 120
BECKMAN COULTER MANUAL IMMUNOASSAYS TODAY 120
BECTON DICKENSON 121
BEIJING WANGER BIOTECHNOLOGY CO. LTD. 121
BHAT BIO-TECH INDIA PRIVATE LTD. 122
BIOO SCIENTIFIC CORP. 122
BIOVENDOR, LLC 122
RESEARCH & DIAGNOSTIC PRODUCTS DIVISION 123
LABORATORY MEDICINE DIVISION 123
CLINICAL PRODUCTS DIVISION 123
PROFESSIONAL CONSULTATION SERVICES 124
BIOMERIEUX SA 124
CANDOR BIOSCIENCE GMBH 124

CAYMAN CHEMICAL CO. 125
DIAMOND DIAGNOSTICS INC. 126
DIASOURCE IMMUNOASSAYS S.A. 126
IBL INTERNATIONAL GMBH 127
IMMUNOCHEMISTRY TECHNOLOGIES LLC 128
HISTORY 128
PRODUCTS, SERVICES, AND RESEARCH 128
IMMUNOSHOP INDIA PVT LTD. 129
INSTITUTE OF ISOTOPES CO. LTD 129
INSTRUMENTATION LABORATORY CO. 130
NOVARTIS VACCINES & DIAGNOSTICS INC. 130
JEI DANIEL BIOTECH CORP. 131
LABOR DIAGNOSTIKA NORD GMBH & CO. KG 131
MICROPOINT BIOSCIENCE INC. 132
ORTHO CLINICAL DIAGNOSTICS 133
PANTEX 133
PROMEGA CORP. 133
QQLAB LLC 134
QUIDEL CORP. 134
RADIOMETER GMBH 136
ROCHE DIAGNOSTICS CORP. 137
SIEMENS HEALTHCARE 137
SYSMEX 137
TRINITY BIOTECH PLC 138
WEIFANG 3V BIOENGINEERING GROUP CO. LTD. 139
WEIFANG KANGHUA BIOTECH CO. LTD. 139
XIAMEN BOSON BIOTECH CO. LTD. 140
ZHEJIANG ZHUJI BETAI BIOTECHNOLOGY CO. LTD. 141
CHAPTER 13 PATENT ANALYSIS 143
INTRODUCTION 143
GLOBAL PATENT TRENDS 143
TABLE 85 GLOBAL PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 143
TABLE 86 GLOBAL PATENT SHARES BY ASSIGNEE 144
U.S. PATENT TRENDS 148
TABLE 87 U.S. PATENT GENERATION TRENDS BY YEARS, 2000-2012 (NO. OF
PATENTS/%) 148
TABLE 88 U.S. PATENT SHARES BY TECHNOLOGY, 2000-2012 149
U.S. PATENT SHARES BY ASSIGNEE 149
TABLE 89 U .S. PATENT SHARES BY ASSIGNEE 2000-2012 149
SAMPLE ABSTRACTS OF U.S. PATENT ABSTRACTS 150
AUTOANTIBODY-ENHANCED IMMUNOASSAYS AND KITS 150

FLUORESCENCE POLARIZATION ASSAYS FOR DETERMINING
CLOSTRIDIAL TOXIN ACTIVITY 150
CHEMILUMINESCENT COMPOSITIONS FOR USE IN DETECTION OF
MULTIPLE ANALYTES 151
U.S. REGISTERED PATENTS 151
TABLE 90 SAMPLE OF U.S. IMMUNOASSAY PATENTS, 2000-2012 152
EUROPEAN PATENT TRENDS 152
TABLE 91 EUROPEAN PATENT GENERATION TRENDS BY YEARS, 2000-2012
(NO. OF PATENTS/%) 152
TABLE 92 EUROPEAN PATENT SHARES BY TECHNOLOGY, 2000-2012 153
EUROPEAN PATENT SHARES BY PATENT HOLDER 153
TABLE 93 EUROPEAN PATENT SHARES BY APPLICATION, 2000-2012 154
SAMPLE ABSTRACTS OF EUROPEAN PATENT ABSTRACTS 155
IMMUNOASSAY PRODUCT AND PROCESS 155
ENZYME IMMUNOASSAY MEMBRANE STRIP WITH CRITICAL VALUE
LINE AND INTERPRETATION METHOD THEREOF 156
FLUORESCENCE IMMUNOASSAY METHOD OF USING ZINC OXIDE
QUANTUM DOTS TO MARK ANTIBODY 156
EUROPEAN REGISTERED PATENTS 156
TABLE 94 SAMPLE OF EUROPEAN IMMUNOASSAY PATENTS, 2000-2012 157
JAPANESE PATENT TRENDS 157
TABLE 95 JAPANESE PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 158
TABLE 96 JAPANESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO. OF
PATENTS/%) 158
JAPANESE PATENT SHARES BY ASSIGNEE 158

TABLE 97 JAPANESE PATENT SHARES BY ASSIGNEE, 2000-2012 (NO. OF
PATENTS/%) 158
SAMPLE ABSTRACTS OF JAPANESE PATENT ABSTRACTS 159
ENZYME IMMUNOASSAY USING ENZYME LABELED ANTIBODY 159
FLUORESCENCE IMMUNOASSAY 160
FLUORESCENT POLYMER MICROPARTICLE, ITS PRODUCTION, AND
REAGENT AND METHOD FOR FLUORO IMMUNOASSAY UTILIZING
THE SAME
160
JAPANESE PATENT REGISTERED PATENTS 161
TABLE 98 SAMPLE OF JAPANESE IMMUNOASSAY PATENTS, 2000-2012 161
CHINESE PATENT TRENDS 161
TABLE 99 CHINESE PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 162
TABLE 100 CHINESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO. OF
PATENTS/%) 162
CHINESE PATENT SHARES BY HOLDER 163
TABLE 101 CHINESE PATENT SHARES BY PATENT HOLDER, 2000-2012 (NO.
OF PATENTS/%) 163
SAMPLE ABSTRACTS OF CHINESE PATENT ABSTRACTS 164
IMMUNOASSAY AND DIAGNOSTIC REAGENT FOR MALARIA 164
ENZYME IMMUNOASSAY KIT FOR COXSACKIE VIRUS B ANTIGEN
AND ITS PREPARING PROCESS 165
VISUAL FLUORESCENCE IMMUNOASSAY METHOD FOR
DETERMINING BIOLOGICAL ACTIVE SUBSTANCE 165
CHINESE PATENTS 165
TABLE 102 SAMPLE OF CHINESE IMMUNOASSAY PATENTS, 2000-2012 166
TAIWANESE PATENT TRENDS 166
TABLE 103 TAIWANESE PATENT GENERATION TRENDS BY YEAR, 2000-2012
(NO. OF PATENTS/%) 167
TABLE 104 TAIWANESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO.
OF PATENTS/%) 167
TABLE 105 TAIWANESE PATENT SHARES BY ASSIGNEE, 2000-2012 (NO. OF
PATENTS/%) 168
SAMPLE ABSTRACTS OF TAIWAN PATENTS 168
IMMUNOASSAY METHOD FOR DETERMINING GLYCOSYLATED
PROTEIN AND TEST LIQUID THEREOF 168
CARRIER-ENZYME-PROTEIN COMPLEX AND IMMUNOASSAY KIT
COMPRISING THE SAME 168
TAIWANESE REGISTERED PATENTS 169
TABLE 106 SAMPLE OF TAIWANESE IMMUNOASSAY PATENTS, 2000-2012 169
SOUTH KOREA PATENT TRENDS 169
TABLE 107 SOUTH KOREAN PATENT GENERATION TRENDS BY YEAR,
2000-2012 (NO. OF PATENTS/%) 170
TABLE 108 SOUTH KOREAN PATENT SHARES BY TECHNOLOGY, 2000-2012
(NO. OF PATENTS/%) 170
TABLE 109 SOUTH KOREAN PATENT SHARES BY ASSIGNEE, 2000-2012 (NO.
OF PATENTS/%) 171
SAMPLE ABSTRACTS OF SOUTH KOREAN PATENTS 172
IMMUNOASSAY METHOD USING MEASUREMENT VALUE LOWERING
INHIBITOR FOR IMMUNOASSAY METHOD 172
METHOD OF IMMUNOASSAY FOR THE DETECTION OF TEICOPLANIN 172
IMMUNOASSAY DEVICE FOR ASSAYING WHOLE BLOOD AND
IMMUNOASSAY METHOD USING THE SAME 173
SOUTH KOREAN REGISTERED PATENTS 173
TABLE 110 SAMPLE OF SOUTH KOREAN IMMUNOASSAY PATENTS,2000-2012 174

LIST OF TABLES

SUMMARY TABLE GLOBAL DEMAND FOR IMMUNOASSAYS BY REGION,
THROUGH 2017 ($ MILLIONS) 7
TABLE 1 ADVANTAGES OF ENZYME IMMUNOASSAY 10
TABLE 2 LIMITATIONS OF ENZYME IMMUNOASSAY 11
TABLE 3 ADVANTAGES OF FLUORESCENT IMMUNOASSAY 11
TABLE 4 LIMITATIONS OF FLUORESCENT IMMUNOASSAY 12
TABLE 5 ADVANTAGES OF RADIOISOTOPES 15
TABLE 6 LIMITATIONS OF RADIOISOTOPES 15
TABLE 7 GLOBAL MEDICAL PRODUCTS MARKET, 2012-2017 ($ BILLIONS) 19
TABLE 8 WESTERN EUROPEAN DEMAND FOR IMMUNOASSAYS BY COUNTRY
THROUGH 2017 ($ MILLIONS) 22
TABLE 9 EASTERN EUROPEAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 25
TABLE 10 ASIAN DEMAND FOR IMMUNOASSAYS BY COUNTRY, THROUGH
2017 ($ MILLIONS) 26
TABLE 11 OCEANIA DEMAND FOR IMMUNOASSAYS BY COUNTRY, THROUGH
2017 ($ MILLIONS) 27
TABLE 12 SOUTHEAST ASIAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 28
TABLE 13 NORTH AMERICAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 29
TABLE 14 CENTRAL AND SOUTH AMERICAN DEMAND FOR IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 30
TABLE 15 NORTH AFRICAN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 31
TABLE 16 SUB-SAHARAN AFRICAN DEMAND FOR IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 32
TABLE 17 MIDDLE EASTERN DEMAND FOR IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 34
TABLE 18 GLOBAL DEMAND FOR ENZYME IMMUNOASSAY BY REGION,
THROUGH 2017 ($ MILLIONS) 37

TABLE 19 WESTERN EUROPEAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 38
TABLE 20 EASTERN EUROPEAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 41
TABLE 21 ASIAN DEMAND FOR ENZYME IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 42
TABLE 22 OCEANIA DEMAND FOR ENZYME IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 43
TABLE 23 SOUTHEAST ASIAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 44
TABLE 24 NORTH AMERICAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 45
TABLE 25 CENTRAL AND SOUTH AMERICAN DEMAND FOR ENZYME
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 46
TABLE 26 NORTH AFRICAN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 47
TABLE 27 SUB-SAHARAN AFRICAN DEMAND FOR ENZYME IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 48
TABLE 28 MIDDLE EASTERN DEMAND FOR ENZYME IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 50
TABLE 29 GLOBAL DEMAND FOR FLUORESCENT IMMUNOASSAYS BY REGION,
THROUGH 2017 ($ MILLIONS) 53
TABLE 30 WESTERN EUROPEAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 54
TABLE 31 EASTERN EUROPEAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 56
TABLE 32 ASIAN DEMAND FOR FLUORESCENT IMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 57
TABLE 33 OCEANIA DEMAND FOR FLUORESCENT IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 58
TABLE 34 SOUTHEAST ASIAN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 58
TABLE 35 NORTH AMERICAN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 59
TABLE 36 CENTRAL AND SOUTH AMERICAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 60
TABLE 37 NORTH AFRICAN DEMAND FOR FLUORESCENT IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 61
TABLE 38 SUB-SARAHAN AFRICAN DEMAND FOR FLUORESCENT
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 62
TABLE 39 MIDDLE EASTERN DEMAND FOR FLUORESCENT IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 63
TABLE 40 GLOBAL DEMAND FOR RADIOIMMUNOASSAYS BY REGION,
THROUGH 2017 ($ MILLIONS) 66
TABLE 41 WESTERN EUROPEAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 67
TABLE 42 EASTERN EUROPEAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 69

TABLE 43 ASIAN DEMAND FOR RADIOIMMUNOASSAY BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 69
TABLE 44 OCEANIAN DEMAND FOR RADIOIMMUNOASSAYS BY COUNTRY,
THROUGH 2017 ($ MILLIONS) 71
TABLE 45 SOUTHEAST ASIAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 71
TABLE 46 NORTH AMERICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 72
TABLE 47 CENTRAL & SOUTH AMERICAN DEMAND FOR RADIO -
IMMUNOASSAYS BY COUNTRY,THROUGH 2017 ($ MILLIONS) 73
TABLE 48 NORTH AFRICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 74
TABLE 49 SUBSARAHAN AFRICAN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 75
TABLE 50 MIDDLE EASTERN DEMAND FOR RADIOIMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 76
TABLE 51 GLOBAL DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 79
TABLE 52 WESTERN EUROPEAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 80
TABLE 53 EASTERN EUROPEAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 82
TABLE 54 ASIAN DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 83
TABLE 55 OCEANIA DEMAND FOR DIABETES LABORATORY IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 84
TABLE 56 SOUTHEAST ASIAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 84
TABLE 57 NORTH AMERICAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 85
TABLE 58 CENTRAL AND SOUTH AMERICAN DEMAND FOR DIABETES
LABORATORY IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 86
TABLE 59 NORTH AFRICAN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 87
TABLE 60 SUBSARAHAN AFRICAN DEMAND FOR DIABETES LABORATORY

IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 87
TABLE 61 MIDDLE EASTERN DEMAND FOR DIABETES LABORATORY
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 89
TABLE 62 GLOBAL DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 92
TABLE 63 WESTERN EUROPEAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 93
TABLE 64 EASTERN EUROPEAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 95
TABLE 65 ASIAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 96
TABLE 66 OCEANIAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 97
TABLE 67 SOUTHEAST ASIAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 97

TABLE 68 NORTH AMERICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 98
TABLE 69 CENTRAL AND SOUTH AMERICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 99
TABLE 70 NORTH AFRICAN DEMAND FOR DRUG SCREENING IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 100
TABLE 71 SUBSAHARIAN AFRICAN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 100
TABLE 72 MIDDLE EASTERN DEMAND FOR DRUG SCREENING
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 102
TABLE 73 GLOBAL DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS BY
REGION, THROUGH 2017 ($ MILLIONS) 105
TABLE 74 WESTERN EUROPEAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 106
TABLE 75 EASTERN EUROPEAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 107
TABLE 76 ASIAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS BY
COUNTRY, THROUGH 2017 ($ MILLIONS) 108
TABLE 77 OCEANIAN DEMAND FOR INFECTIOUS DISEASE IMMUNOASSAYS
BY COUNTRY, THROUGH 2017 ($ MILLIONS) 109
TABLE 78 SOUTHEAST ASIAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 109
TABLE 79 NORTH AMERICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 110
TABLE 80 CENTRAL AND SOUTH AMERICAN DEMAND FOR INFECTIOUS
DISEASE IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 111
TABLE 81 NORTH AFRICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 112
TABLE 82 SUBSARAHAN AFRICAN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 113
TABLE 83 MIDDLE EASTERN DEMAND FOR INFECTIOUS DISEASE
IMMUNOASSAYS BY COUNTRY, THROUGH 2017 ($ MILLIONS) 114
TABLE 84 RANKING OF LEADING IMMUNOASSAY TECHNOLOGY

MANUFACTURERS 117
TABLE 85 GLOBAL PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 143
TABLE 86 GLOBAL PATENT SHARES BY ASSIGNEE 144
TABLE 87 U.S. PATENT GENERATION TRENDS BY YEARS, 2000-2012 (NO. OF
PATENTS/%) 148
TABLE 88 U.S. PATENT SHARES BY TECHNOLOGY, 2000-2012 149
TABLE 89 U .S. PATENT SHARES BY ASSIGNEE 2000-2012 149
TABLE 90 SAMPLE OF U.S. IMMUNOASSAY PATENTS, 2000-2012 152
TABLE 91 EUROPEAN PATENT GENERATION TRENDS BY YEARS, 2000-2012
(NO. OF PATENTS/%) 152
TABLE 92 EUROPEAN PATENT SHARES BY TECHNOLOGY, 2000-2012 153
TABLE 93 EUROPEAN PATENT SHARES BY APPLICATION, 2000-2012 154
TABLE 94 SAMPLE OF EUROPEAN IMMUNOASSAY PATENTS, 2000-2012 157
TABLE 95 JAPANESE PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 158
TABLE 96 JAPANESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO. OF
PATENTS/%) 158
TABLE 97 JAPANESE PATENT SHARES BY ASSIGNEE, 2000-2012 (NO. OF
PATENTS/%) 158
TABLE 98 SAMPLE OF JAPANESE IMMUNOASSAY PATENTS, 2000-2012 161
TABLE 99 CHINESE PATENT GENERATION TRENDS BY YEAR, 2000-2012 (NO.
OF PATENTS/%) 162
TABLE 100 CHINESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO. OF
PATENTS/%) 162
TABLE 101 CHINESE PATENT SHARES BY PATENT HOLDER, 2000-2012 (NO. OF
PATENTS/%) 163
TABLE 102 SAMPLE OF CHINESE IMMUNOASSAY PATENTS, 2000-2012 166
TABLE 103 TAIWANESE PATENT GENERATION TRENDS BY YEAR, 2000-2012
(NO. OF PATENTS/%) 167
TABLE 104 TAIWANESE PATENT SHARES BY TECHNOLOGY, 2000-2012 (NO. OF
PATENTS/%) 167
TABLE 105 TAIWANESE PATENT SHARES BY ASSIGNEE, 2000-2012 (NO. OF
PATENTS/%) 168
TABLE 106 SAMPLE OF TAIWANESE IMMUNOASSAY PATENTS, 2000-2012 169
TABLE 107 SOUTH KOREAN PATENT GENERATION TRENDS BY YEAR,
2000-2012 (NO. OF PATENTS/%) 170
TABLE 108 SOUTH KOREAN PATENT SHARES BY TECHNOLOGY, 2000-2012
(NO. OF PATENTS/%) 170
TABLE 109 SOUTH KOREAN PATENT SHARES BY ASSIGNEE, 2000-2012 (NO.
OF PATENTS/%) 171
TABLE 110 SAMPLE OF SOUTH KOREAN IMMUNOASSAY PATENTS,2000-2012 174

LIST OF FIGURES

SUMMARY FIGURE GLOBAL DEMAND FOR IMMUNOASSAYS BY REGION,
2011-2017 ($ MILLIONS) 7

Read the full report:
Immunoassays: Technologies and Global Markets

http://www.reportbuyer.com/pharma_healthcare/technology/immunoassays_technologies_global_markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.